Quintrio
Home

Stock overview

InflaRx N.V. Common Stock

IFRX

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Last trade $1.15
Day change -$0.03 (-2.54%)
Day range $1.09 – $1.23
Volume 569,270
Market cap $174M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for IFRX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for IFRX.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now

InflaRx N.V. (IFRX) has formed a hammer chart pattern after an 8.5% weekly decline, suggesting potential trend reversal. The stock is supported by rising analyst optimism, with consensus EPS estimates increasing 29.5% over the last 30 days. IFRX holds a Zacks Rank #2 (Buy) rating, placing it in the top 20% of rated stocks.

GlobeNewswire Inc.

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

InflaRx announced pre-clinical data demonstrating that izicopan, an oral C5a receptor inhibitor, robustly inhibited inflammatory responses and provided renal protection in kidney disease models. The data showed significant improvements in renal function markers and histopathological scores in both acute kidney injury and progressive renal injury models. Structural modeling revealed izicopan's differentiated molecular profile with reduced drug-drug interaction potential compared to competitors.

GlobeNewswire Inc.

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

InflaRx N.V. (Nasdaq: IFRX) announced it received a notice from Nasdaq on March 11, 2026, indicating that its ordinary shares have closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until September 7, 2026, to regain compliance, with a potential additional 180-day grace period if it transfers to the Nasdaq Capital Market. The notice has no immediate effect on trading.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.